GlaxoSmithKline : Q2 beats forecasts, guidance raised
>Xevudy and Shingrix drive growth - GSK reported a Q2 that beat estimates for sales (+10% vs consensus) and its core EPS (+18% vs consensus), thanks to a strong contribution from Xevudy (£ 466m vs consensus £ 97m) and significant rebound at Shingrix (+148%) in line with Q1 (+114%). Global sales were up 13% CER. After a tricky year for Shingrix, we see a very strong rebound in drug sales far above the consensus (£ 731m vs consensus of £ 610m). Group core EBIT was up by...GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.